阿替普酶治疗急性脑梗死的疗效

被引：8

作者：

王云 ^{[1
]}

刘定华 ^{[1
]}

吴伟 ^{[2
]}

机构：

[1] 江阴市人民医院神经内科

[2] 江阴市人民医院神经科ICU

来源：

江苏医药 | 2013年 / 39卷 / 16期

关键词：

阿替普酶; 急性脑梗死; 溶栓;

D O I：

10.19460/j.cnki.0253-3685.2013.16.020

中图分类号：

R743.33 [脑栓塞];

学科分类号：

1002 ;

摘要：

目的探讨阿替普酶(rt-PA)静脉溶栓治疗急性脑梗死(ACI)的临床疗效和安全性。方法选择4.5h内的ACI患者64例分别采用rt-PA 0.6mg/kg(最大剂量为60mg)(A组,30例)和rt-PA 0.9mg/kg(最大剂量为90mg)(B组,34例)。治疗后24h、7、28和90d用NIHSS量表评估疗效;比较治疗前和治疗后90d的改良Rankin评分和日常生活(ADL)量表评分;以治疗期间颅内出血发生率和90d内病死率评估安全性。结果两组治疗后NIHSS评分均比治疗前明显改善(P<0.01)。90d内颅内出血:A组2例(6.6%),B组4例(11.7%)。90d内死亡:A组1例(3.3%),B组3例(8.8%)。结论应用低剂量静脉溶栓治疗发病4.5h内的ACI有效、安全。

引用

页码：1923 / 1925

页数：3

共 7 条

[1] 脑梗死超早期的溶栓治疗 [J].

黄如训 .

中华医学杂志, 2004, (12) :83-85

[2]

Low-Dose Intravenous Recombinant Tissue-Type Plasminogen Activator Therapy for Patients With Stroke Outside European Indications: Stroke Acute Management with Urgent Risk-factor Assessment and Improvement (SAMURAI) rtPA Registry [J] . Masatoshi Koga,Yoshiaki Shiokawa,Jyoji Nakagawara,Eisuke Furui,Kazumi Kimura,Hiroshi Yamagami,Yasushi Okada,Yasuhiro Hasegawa,Kazuomi Kario,Satoshi Okuda,Kaoru Endo,Tetsuya Miyagi,Masato Osaki,Kazuo Minematsu,Kazunori Toyoda.&nbsp&nbspStroke .

[3] Role of Tissue Plasminogen Activator in Acute Ischemic Stroke [J].

Hatcher, Molly A. ;

Starr, Jessica A. .

ANNALS OF PHARMACOTHERAPY, 2011, 45 (03) :364-371

[4]

Thrombolysis With 0.6 mg/kg Intravenous Alteplase for Acute Ischemic Stroke in Routine Clinical Practice: The Japan post-Marketing Alteplase Registration Study (J-MARS) [J] . Jyoji Nakagawara,Kazuo Minematsu,Yasushi Okada,Norio Tanahashi,Shinji Nagahiro,Etsuro Mori,Yukito Shinohara,Takenori Yamaguchi.&nbsp&nbspStroke . 2010 (9)

[5]

Alteplase at 0.6 mg/kg for Acute Ischemic Stroke Within 3 Hours of Onset: Japan Alteplase Clinical Trial (J-ACT) [J] . Takenori Yamaguchi,Etsuro Mori,Kazuo Minematsu,Jyoji Nakagawara,Kazuo Hashi,Isamu Saito,Yukito Shinohara.&nbsp&nbspStroke . 2006 (7)

[6]

Ultrasound Identification and Lysis of Clots [J] . Andrei V. Alexandrov.&nbsp&nbspStroke . 2004 (11 S)

[7] Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) [J].

Hacke, W ;

Kaste, M ;

Fieschi, C ;

von Kummer, R ;

Davalos, A ;

Meier, D ;

Larrue, V ;

Bluhmki, E ;

Davis, S ;

Donnan, G ;

Schneider, D ;

Diez-Tejedor, E ;

Trouillas, P .

LANCET, 1998, 352 (9136) :1245-1251

← 1 →